Clinical Trial: Galantamine Effects in Patients With Metabolic Syndrome
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Effects of Cholinergic Stimulation on Visceral Fat, Oxidative Stress and Inflammatory Markers in Patients With Metabolic Syndrome: a Randomized Clinical Trial
Brief Summary: It is recognized that inflammation can be modulated by cholinergic stimulation and that galantamine, an inhibitor of acetylcholinesterase enzyme with central nervous system action, has showed an anti-inflammatory effect, reducing body weight, abdominal fat and improvement in tissue insulin resistance in animal models. Galantamine is a safe drug that is used to treat alzheimer disease.Galantamine treatments of patients with the metabolic syndrome may represent a significant advance in management of this disease. This study aims to investigate the effects of galantamine on inflammatory markers, as well as on abdominal visceral and epicardial fat and oxidative stress in patients with metabolic syndrome. This is a pioneering study that will include expert support. The enrolling of subjects will have continuous monitoring throughout the period of treatment. The study is a double blind randomized prospective study with 60 patients with metabolic syndrome, to be randomized at ratio of 1: 1 placebo and galantamine. The dose of galanthamine is the standard clinically approved (8 and 16 mg). The tracking method include metabolic analysis, inflammatory and oxidative stress markers, hemodynamic evaluation with hear rate variability (sympatho vagal modulation) before, during and after treatment. Computerized tomography assessment of visceral abdominal and epicardial fat before and after treatment will be performed.
Detailed Summary:
Population: patients with metabolic syndrome; Intervention: Galantamine; Comparation: Placebo; Outcomes (primary): proinflammatory cytokines levels.
Description:
Patients with criteria of Metabolic Syndrome (with the 2005 revised NCEP ATP III criteria) will be randomized to 2 groups: use of galantamina (30 patients) or placebo (30 patients) in the following sequency:
I) 4 weeks of treatment with 8 mg of galantamine or placedo (oral ingestion capsules);
II) 8 weeks of treatment with 16 mg of galantamine or placebo (oral ingestion capsules).
Participants will receive a diary to record any symptoms that may present and will be instructed to bring it at each study visit.
Before randomization all participants will go through the following procedures:
- Clinical and neurological evaluation;
- Blood sample analysis of cytokines, oxidative stress and biochemical parameters;
- Multidetector computed tomographic (MDCT) scan of abdomen (visceral - abdominal and epicardial fat) and thorax (calcium score);
- blood pressure recording for hemodynamic evaluation and assessment of heart rate variability
- 24h ambulatory blood pressure measurement
These procedures will be repeated at the end of the protocol.
This is a randomized controlled trial study. Blinding status: Patients, investigators, and outcome assessors.
Original Secondary Outcome:
- Composite measure of markers of oxidative stress, to include: total amount of free radicals, malondialdehyde, allantoin, alpha1-antiproteinase, oxidized/reduced glutathione ratio, high-sensitive C-reactive protein, fibrinogen. [ Time Frame: 12 weeks ]
- Epicardial and abdominal fat levels [ Time Frame: 12 weeks ]
- Arterial blood pressure levels [ Time Frame: 12 weeks ]
- High density lipoprotein cholesteral levels [ Time Frame: 12 weeks ]
- Triglycerides levels [ Time Frame: 12 weeks ]
Information By: University of Sao Paulo
Dates:
Date Received: October 7, 2014
Date Started: March 2014
Date Completion:
Last Updated: February 13, 2017
Last Verified: February 2017
